Immunomodulatory functions of type I interferons (original) (raw)

• Jenner, E. Letter to the Editor. Med. Phys. J. 12, 97–102 (1804).
  PubMed PubMed Central Google Scholar
• Salaman, R. N. Protective inoculation against a plant virus. Nature 131, 468 (1933).
  Article Google Scholar
• White, P. B. Lysogenic strains of V. cholerae and the influence of lysozyme on cholera phage activity. J. Pathol. Bacteriol. 44, 276–278 (1937).
  Article Google Scholar
• Hoskins, M. A protective action of neurotropic against viscerotropic yellow fever virus in Macacus rhesus. Am. J. Trop. Med. 15, 675–680 (1935).
  Article Google Scholar
• Isaacs, A. & Lindenmann, J. Virus interference. I. The interferon. Proc. R. Soc. Lond. B Biol. Sci. 147, 258–267 (1957).
  Article CAS PubMed Google Scholar
• Pestka, S., Krause, C. D. & Walter, M. R. Interferons, interferon-like cytokines, and their receptors. Immunol. Rev. 202, 8–32 (2004).
  Article CAS PubMed Google Scholar
• Gad, H. H. et al. Interferon-λ is functionally an interferon but structurally related to the interleukin-10 family. J. Biol. Chem. 284, 20869–20875 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Hacker, H. et al. Specificity in Toll-like receptor signalling through distinct effector functions of TRAF3 and TRAF6. Nature 439, 204–207 (2006). This study showed that TRAF3 is essential for both type I IFN and IL-10 production, but dispensable for the production of pro-inflammatory cytokines.
  Article PubMed CAS Google Scholar
• Schafer, S. L., Lin, R., Moore, P. A., Hiscott, J. & Pitha, P. M. Regulation of type I interferon gene expression by interferon regulatory factor-3. J. Biol. Chem. 273, 2714–2720 (1998).
  Article CAS PubMed Google Scholar
• Monroe, K. M., McWhirter, S. M. & Vance, R. E. Induction of type I interferons by bacteria. Cell. Microbiol. 12, 881–890 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Trinchieri, G. Type I interferon: friend or foe? J. Exp. Med. 207, 2053–2063 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Akira, S. Toll-like receptors and innate immunity. Adv. Immunol. 78, 1–56 (2001).
  Article CAS PubMed Google Scholar
• Barber, G. N. Innate immune DNA sensing pathways: STING, AIMII and the regulation of interferon production and inflammatory responses. Curr. Opin. Immunol. 23, 10–20 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Kawai, T. & Akira, S. The roles of TLRs, RLRs and NLRs in pathogen recognition. Int. Immunol. 21, 317–337 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Ishikawa, H., Ma, Z. & Barber, G. N. STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity. Nature 461, 788–792 (2009). A description of STING as an important mediator in the host defence response against DNA-containing pathogens and in the adjuvant activity of DNA-based vaccines.
  Article CAS PubMed PubMed Central Google Scholar
• Takaoka, A. et al. DAI (DLM-1/ZBP1) is a cytosolic DNA sensor and an activator of innate immune response. Nature 448, 501–505 (2007). The first identification of DAI as a new cytosolic DNA sensor that enhances the induction of type I IFN genes and other genes involved in innate immunity.
  Article CAS PubMed Google Scholar
• Kaiser, W. J., Upton, J. W. & Mocarski, E. S. Receptor-interacting protein homotypic interaction motif-dependent control of NF-κB activation via the DNA-dependent activator of IFN regulatory factors. J. Immunol. 181, 6427–6434 (2008).
  Article CAS PubMed Google Scholar
• Ishii, K. J. et al. TANK-binding kinase-1 delineates innate and adaptive immune responses to DNA vaccines. Nature 451, 725–729 (2008).
  Article CAS PubMed Google Scholar
• Chiu, Y. H., Macmillan, J. B. & Chen, Z. J. RNA polymerase III detects cytosolic DNA and induces type I interferons through the RIG-I pathway. Cell 138, 576–591 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Honda, K. & Taniguchi, T. IRFs: master regulators of signalling by Toll-like receptors and cytosolic pattern-recognition receptors. Nature Rev. Immunol. 6, 644–658 (2006).
  Article CAS Google Scholar
• Platanias, L. C. Mechanisms of type-I- and type-II-interferon-mediated signalling. Nature Rev. Immunol. 5, 375–386 (2005). An excellent review of the signalling mechanisms of type I IFNs, including the classical JAK–STAT pathways, as well as the MAPK and mTOR pathways.
  Article CAS Google Scholar
• Fasler-Kan, E., Pansky, A., Wiederkehr, M., Battegay, M. & Heim, M. H. Interferon-α activates signal transducers and activators of transcription 5 and 6 in Daudi cells. Eur. J. Biochem. 254, 514–519 (1998).
  Article CAS PubMed Google Scholar
• Matikainen, S. et al. Interferon-α activates multiple STAT proteins and upregulates proliferation-associated IL-2R α, c-myc, and pim-1 genes in human T cells. Blood 93, 1980–1991 (1999).
  CAS PubMed Google Scholar
• Aaronson, D. S. & Horvath, C. M. A road map for those who don't know JAK–STAT. Science 296, 1653–1655 (2002).
  Article CAS PubMed Google Scholar
• Platanias, L. C. & Fish, E. N. Signaling pathways activated by interferons. Exp. Hematol. 27, 1583–1592 (1999).
  Article CAS PubMed Google Scholar
• Sato, T., Selleri, C., Young, N. S. & Maciejewski, J. P. Inhibition of interferon regulatory factor-1 expression results in predominance of cell growth stimulatory effects of interferon-γ due to phosphorylation of Stat1 and Stat3. Blood 90, 4749–4758 (1997).
  CAS PubMed Google Scholar
• Heinrich, P. C., Behrmann, I., Muller-Newen, G., Schaper, F. & Graeve, L. Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem. J. 334, 297–314 (1998).
  Article CAS PubMed PubMed Central Google Scholar
• Baker, S. J., Rane, S. G. & Reddy, E. P. Hematopoietic cytokine receptor signaling. Oncogene 26, 6724–6737 (2007).
  Article CAS PubMed Google Scholar
• Regis, G., Pensa, S., Boselli, D., Novelli, F. & Poli, V. Ups and downs: the STAT1:STAT3 seesaw of interferon and gp130 receptor signalling. Semin. Cell Dev. Biol. 19, 351–359 (2008).
  Article CAS PubMed Google Scholar
• Stephanou, A., Brar, B. K., Knight, R. A. & Latchman, D. S. Opposing actions of STAT-1 and STAT-3 on the Bcl-2 and Bcl-x promoters. Cell Death Differ. 7, 329–330 (2000).
  Article CAS PubMed Google Scholar
• Azare, J. et al. Constitutively activated Stat3 induces tumorigenesis and enhances cell motility of prostate epithelial cells through integrin β6. Mol. Cell. Biol. 27, 4444–4453 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Dechow, T. N. et al. Requirement of matrix metalloproteinase-9 for the transformation of human mammary epithelial cells by Stat3-C. Proc. Natl Acad. Sci. USA 101, 10602–10607 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Dustin, M. L., Singer, K. H., Tuck, D. T. & Springer, T. A. Adhesion of T lymphoblasts to epidermal keratinocytes is regulated by interferon γ and is mediated by intercellular adhesion molecule 1 (ICAM-1). J. Exp. Med. 167, 1323–1340 (1988).
  Article CAS PubMed Google Scholar
• Yoshimura, A. Signal transduction of inflammatory cytokines and tumor development. Cancer Sci. 97, 439–447 (2006).
  Article CAS PubMed Google Scholar
• Brucet, M., Marques, L., Sebastian, C., Lloberas, J. & Celada, A. Regulation of murine Tap1 and Lmp2 genes in macrophages by interferon γ is mediated by STAT1 and IRF-1. Genes Immun. 5, 26–35 (2004).
  Article CAS PubMed Google Scholar
• Marques, L., Brucet, M., Lloberas, J. & Celada, A. STAT1 regulates lipopolysaccharide- and TNF-α-dependent expression of transporter associated with antigen processing 1 and low molecular mass polypeptide 2 genes in macrophages by distinct mechanisms. J. Immunol. 173, 1103–1110 (2004).
  Article CAS PubMed Google Scholar
• Ito, S. et al. Interleukin-10 inhibits expression of both interferon α- and interferon γ-induced genes by suppressing tyrosine phosphorylation of STAT1. Blood 93, 1456–1463 (1999).
  CAS PubMed Google Scholar
• Yasukawa, H. et al. IL-6 induces an anti-inflammatory response in the absence of SOCS3 in macrophages. Nature Immunol. 4, 551–556 (2003).
  Article CAS Google Scholar
• El Kasmi, K. C. et al. General nature of the STAT3-activated anti-inflammatory response. J. Immunol. 177, 7880–7888 (2006).
  Article CAS PubMed Google Scholar
• Tanabe, Y. et al. Cutting edge: role of STAT1, STAT3, and STAT5 in IFN-αβ responses in T lymphocytes. J. Immunol. 174, 609–613 (2005).
  Article CAS PubMed Google Scholar
• Qing, Y. & Stark, G. R. Alternative activation of STAT1 and STAT3 in response to interferon-γ. J. Biol. Chem. 279, 41679–41685 (2004).
  Article CAS PubMed Google Scholar
• Chang, E. Y., Guo, B., Doyle, S. E. & Cheng, G. Cutting edge: involvement of the type I IFN production and signaling pathway in lipopolysaccharide-induced IL-10 production. J. Immunol. 178, 6705–6709 (2007).
  Article CAS PubMed Google Scholar
• Wang, X., Chen, M., Wandinger, K. P., Williams, G. & Dhib-Jalbut, S. IFN-β-1b inhibits IL-12 production in peripheral blood mononuclear cells in an IL-10-dependent mechanism: relevance to IFN-β-1b therapeutic effects in multiple sclerosis. J. Immunol. 165, 548–557 (2000).
  Article CAS PubMed Google Scholar
• Ziegler-Heitbrock, L. et al. IFN-α induces the human IL-10 gene by recruiting both IFN regulatory factor 1 and Stat3. J. Immunol. 171, 285–290 (2003).
  Article CAS PubMed Google Scholar
• Wang, H. et al. The role of glycogen synthase kinase 3 in regulating IFN-β-mediated IL-10 production. J. Immunol. 186, 675–684 (2011).
  Article CAS PubMed Google Scholar
• Uddin, S. et al. Activation of the p38 mitogen-activated protein kinase by type I interferons. J. Biol. Chem. 274, 30127–30131 (1999).
  Article CAS PubMed Google Scholar
• Uddin, S. et al. The Rac1/p38 mitogen-activated protein kinase pathway is required for interferon α-dependent transcriptional activation but not serine phosphorylation of Stat proteins. J. Biol. Chem. 275, 27634–27640 (2000).
  CAS PubMed Google Scholar
• Li, Y. et al. Role of p38α Map kinase in type I interferon signaling. J. Biol. Chem. 279, 970–979 (2004).
  Article CAS PubMed Google Scholar
• Mayer, I. A. et al. The p38 MAPK pathway mediates the growth inhibitory effects of interferon-α in BCR-ABL-expressing cells. J. Biol. Chem. 276, 28570–28577 (2001).
  Article CAS PubMed Google Scholar
• Ishida, H. et al. Involvement of p38 signaling pathway in interferon-α-mediated antiviral activity toward hepatitis C virus. Biochem. Biophys. Res. Commun. 321, 722–727 (2004).
  Article CAS PubMed Google Scholar
• David, M. et al. Requirement for MAP kinase (ERK2) activity in interferon α- and interferon β-stimulated gene expression through STAT proteins. Science 269, 1721–1723 (1995).
  Article CAS PubMed Google Scholar
• Wang, F. et al. Disruption of Erk-dependent type I interferon induction breaks the myxoma virus species barrier. Nature Immunol. 5, 1266–1274 (2004).
  Article CAS Google Scholar
• Uddin, S. et al. Interferon-α engages the insulin receptor substrate-1 to associate with the phosphatidylinositol 3′-kinase. J. Biol. Chem. 270, 15938–15941 (1995).
  Article CAS PubMed Google Scholar
• Kaur, S. et al. Role of the Akt pathway in mRNA translation of interferon-stimulated genes. Proc. Natl Acad. Sci. USA 105, 4808–4813 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Kaur, S. et al. Dual regulatory roles of phosphatidylinositol 3-kinase in IFN signaling. J. Immunol. 181, 7316–7323 (2008).
  Article CAS PubMed Google Scholar
• Lekmine, F. et al. Activation of the p70 S6 kinase and phosphorylation of the 4E-BP1 repressor of mRNA translation by type I interferons. J. Biol. Chem. 278, 27772–27780 (2003).
  Article CAS PubMed Google Scholar
• Lekmine, F. et al. Interferon-γ engages the p70 S6 kinase to regulate phosphorylation of the 40S S6 ribosomal protein. Exp. Cell Res. 295, 173–182 (2004).
  Article CAS PubMed Google Scholar
• Matsumoto, A. et al. Interferon-α-induced mTOR activation is an anti-hepatitis C virus signal via the phosphatidylinositol 3-kinase–Akt-independent pathway. J. Gastroenterol. 44, 856–863 (2009).
  Article CAS PubMed Google Scholar
• Round, J. L. & Mazmanian, S. K. The gut microbiota shapes intestinal immune responses during health and disease. Nature Rev. Immunol. 9, 313–323 (2009).
  Article CAS Google Scholar
• Katakura, K. et al. Toll-like receptor 9-induced type I IFN protects mice from experimental colitis. J. Clin. Invest. 115, 695–702 (2005). This study demonstrated that the protective effect of TLR9 signalling in colonic injury is mediated by type I IFNs.
  Article CAS PubMed PubMed Central Google Scholar
• Rachmilewitz, D. et al. Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis. Gastroenterology 126, 520–528 (2004).
  Article CAS PubMed Google Scholar
• Vijay-Kumar, M. et al. Activation of Toll-like receptor 3 protects against DSS-induced acute colitis. Inflamm. Bowel Dis. 13, 856–864 (2007).
  Article PubMed Google Scholar
• McFarland, A. P. et al. Localized delivery of interferon-β by Lactobacillus exacerbates experimental colitis. PloS ONE 6, e16967 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Abe, K. et al. Conventional dendritic cells regulate the outcome of colonic inflammation independently of T cells. Proc. Natl Acad. Sci. USA 104, 17022–17027 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Hall, J. A. et al. Commensal DNA limits regulatory T cell conversion and is a natural adjuvant of intestinal immune responses. Immunity 29, 637–649 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Hofmann, C. et al. T cell-dependent protective effects of CpG motifs of bacterial DNA in experimental colitis are mediated by CD11c+ dendritic cells. Gut 59, 1347–1354 (2010).
  Article CAS PubMed Google Scholar
• Bleich, A. et al. CpG motifs of bacterial DNA exert protective effects in mouse models of IBD by antigen-independent tolerance induction. Gastroenterology 136, 278–287 (2009).
  Article PubMed Google Scholar
• Bilsborough, J., George, T. C., Norment, A. & Viney, J. L. Mucosal CD8α+ DC, with a plasmacytoid phenotype, induce differentiation and support function of T cells with regulatory properties. Immunology 108, 481–492 (2003).
  CAS PubMed PubMed Central Google Scholar
• Levings, M. K. et al. IFN-α and IL-10 induce the differentiation of human type 1 T regulatory cells. J. Immunol. 166, 5530–5539 (2001).
  Article CAS PubMed Google Scholar
• Szabo, S. J. et al. Distinct effects of T-bet in TH1 lineage commitment and IFN-γ production in CD4 and CD8 T cells. Science 295, 338–342 (2002).
  Article CAS PubMed Google Scholar
• Cho, S. S. et al. Activation of STAT4 by IL-12 and IFN-α: evidence for the involvement of ligand-induced tyrosine and serine phosphorylation. J. Immunol. 157, 4781–4789 (1996).
  CAS PubMed Google Scholar
• Rogge, L. et al. The role of Stat4 in species-specific regulation of Th cell development by type I IFNs. J. Immunol. 161, 6567–6574 (1998).
  CAS PubMed Google Scholar
• Cousens, L. P. et al. Two roads diverged: interferon α/β- and interleukin 12-mediated pathways in promoting T cell interferon γ responses during viral infection. J. Exp. Med. 189, 1315–1328 (1999).
  Article CAS PubMed PubMed Central Google Scholar
• Nguyen, K. B. et al. Critical role for STAT4 activation by type 1 interferons in the interferon-γ response to viral infection. Science 297, 2063–2066 (2002).
  Article CAS PubMed Google Scholar
• Berenson, L. S., Farrar, J. D., Murphy, T. L. & Murphy, K. M. Frontline: absence of functional STAT4 activation despite detectable tyrosine phosphorylation induced by murine IFN-α. Eur. J. Immunol. 34, 2365–2374 (2004).
  Article CAS PubMed Google Scholar
• Farrar, J. D., Smith, J. D., Murphy, T. L. & Murphy, K. M. Recruitment of Stat4 to the human interferon-α/β receptor requires activated Stat2. J. Biol. Chem. 275, 2693–2697 (2000).
  Article CAS PubMed Google Scholar
• Berenson, L. S., Gavrieli, M., Farrar, J. D., Murphy, T. L. & Murphy, K. M. Distinct characteristics of murine STAT4 activation in response to IL-12 and IFN-α. J. Immunol. 177, 5195–5203 (2006).
  Article CAS PubMed Google Scholar
• Huber, J. P. & Farrar, J. D. Regulation of effector and memory T-cell functions by type I interferon. Immunology 132, 466–474 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Matikainen, S. et al. IFN-α and IL-18 synergistically enhance IFN-γ production in human NK cells: differential regulation of Stat4 activation and IFN-γ gene expression by IFN-α and IL-12. Eur. J. Immunol. 31, 2236–2245 (2001).
  Article CAS PubMed Google Scholar
• Strengell, M., Julkunen, I. & Matikainen, S. IFN-α regulates IL-21 and IL-21R expression in human NK and T cells. J. Leukoc. Biol. 76, 416–422 (2004).
  Article CAS PubMed Google Scholar
• Harrington, L. E. et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nature Immunol. 6, 1123–1132 (2005).
  Article CAS Google Scholar
• Moschen, A. R., Geiger, S., Krehan, I., Kaser, A. & Tilg, H. Interferon-α controls IL-17 expression in vitro and in vivo. Immunobiology 213, 779–787 (2008).
  Article CAS PubMed Google Scholar
• Qiu, H. et al. Type I IFNs enhance susceptibility to Chlamydia muridarum lung infection by enhancing apoptosis of local macrophages. J. Immunol. 181, 2092–2102 (2008).
  Article CAS PubMed Google Scholar
• Karaghiosoff, M. et al. Central role for type I interferons and Tyk2 in lipopolysaccharide-induced endotoxin shock. Nature Immunol. 4, 471–477 (2003).
  Article CAS Google Scholar
• Vandenbark, A. A. et al. Interferon-β-1a treatment increases CD56bright natural killer cells and CD4+CD25+ Foxp3 expression in subjects with multiple sclerosis. J. Neuroimmunol. 215, 125–128 (2009).
  Article CAS PubMed Google Scholar
• Zhou, X. et al. Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo. Nature Immunol. 10, 1000–1007 (2009).
  Article CAS Google Scholar
• Oldenhove, G. et al. Decrease of Foxp3+ Treg cell number and acquisition of effector cell phenotype during lethal infection. Immunity 31, 772–786 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Dominguez-Villar, M., Baecher-Allan, C. M. & Hafler, D. A. Identification of T helper type 1-like, Foxp3+ regulatory T cells in human autoimmune disease. Nature Med. 17, 673–675 (2011).
  Article CAS PubMed Google Scholar
• Schroder, K. & Tschopp, J. The inflammasomes. Cell 140, 821–832 (2010).
  Article CAS PubMed Google Scholar
• Guarda, G. et al. Type I interferon inhibits interleukin-1 production and inflammasome activation. Immunity 34, 213–223 (2011). An important study showing that type I IFN signalling inhibits NLRP1 and NLRP3 inflammasomes in a two-step process through STAT1 and IL-10.
  Article CAS PubMed Google Scholar
• Henry, T., Brotcke, A., Weiss, D. S., Thompson, L. J. & Monack, D. M. Type I interferon signaling is required for activation of the inflammasome during Francisella infection. J. Exp. Med. 204, 987–994 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Fernandes-Alnemri, T. et al. The AIM2 inflammasome is critical for innate immunity to Francisella tularensis. Nature Immunol. 11, 385–393 (2010).
  Article CAS Google Scholar
• Fujita, T. et al. Induction of the transcription factor IRF-1 and interferon-β mRNAs by cytokines and activators of second-messenger pathways. Proc. Natl Acad. Sci. USA 86, 9936–9940 (1989).
  Article CAS PubMed PubMed Central Google Scholar
• Rivieccio, M. A. et al. The cytokine IL-1β activates IFN response factor 3 in human fetal astrocytes in culture. J. Immunol. 174, 3719–3726 (2005).
  Article CAS PubMed Google Scholar
• Gonzalez-Navajas, J. M. et al. Interleukin 1 receptor signaling regulates DUBA expression and facilitates Toll-like receptor 9-driven antiinflammatory cytokine production. J. Exp. Med. 207, 2799–2807 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Tseng, P. H. et al. Different modes of ubiquitination of the adaptor TRAF3 selectively activate the expression of type I interferons and proinflammatory cytokines. Nature Immunol. 11, 70–75 (2010). An elegant study showing the different effects of K63- and K48-linked polyubiquitylation on the biological functions of TRAF3.
  Article CAS Google Scholar
• Kayagaki, N. et al. DUBA: a deubiquitinase that regulates type I interferon production. Science 318, 1628–1632 (2007). The first report that DUBA binds to TRAF3 and selectively cleaves the K63-linked polyubiquitin chains, thereby dampening type I IFN production.
  Article CAS PubMed Google Scholar
• Lebeis, S. L., Powell, K. R., Merlin, D., Sherman, M. A. & Kalman, D. Interleukin-1 receptor signaling protects mice from lethal intestinal damage caused by the attaching and effacing pathogen Citrobacter rodentium. Infect. Immun. 77, 604–614 (2009).
  Article CAS PubMed Google Scholar
• Kojouharoff, G. et al. Neutralization of tumour necrosis factor (TNF) but not of IL-1 reduces inflammation in chronic dextran sulphate sodium-induced colitis in mice. Clin. Exp. Immunol. 107, 353–358 (1997).
  Article CAS PubMed PubMed Central Google Scholar
• Auerbuch, V., Brockstedt, D. G., Meyer-Morse, N., O'Riordan, M. & Portnoy, D. A. Mice lacking the type I interferon receptor are resistant to Listeria monocytogenes. J. Exp. Med. 200, 527–533 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Carrero, J. A., Calderon, B. & Unanue, E. R. Type I interferon sensitizes lymphocytes to apoptosis and reduces resistance to Listeria infection. J. Exp. Med. 200, 535–540 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Stanley, S. A., Johndrow, J. E., Manzanillo, P. & Cox, J. S. The type I IFN response to infection with Mycobacterium tuberculosis requires ESX-1-mediated secretion and contributes to pathogenesis. J. Immunol. 178, 3143–3152 (2007).
  Article CAS PubMed Google Scholar
• Nagarajan, U. M. et al. Type I interferon signaling exacerbates Chlamydia muridarum genital infection in a murine model. Infect. Immun. 76, 4642–4648 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Henry, T. et al. Type I IFN signaling constrains IL-17A/F secretion by γδ T cells during bacterial infections. J. Immunol. 184, 3755–3767 (2010).
  Article CAS PubMed Google Scholar
• Carrero, J. A. & Unanue, E. R. Lymphocyte apoptosis as an immune subversion strategy of microbial pathogens. Trends Immunol. 27, 497–503 (2006).
  Article CAS PubMed Google Scholar
• Mancuso, G. et al. Type I IFN signaling is crucial for host resistance against different species of pathogenic bacteria. J. Immunol. 178, 3126–3133 (2007).
  Article CAS PubMed Google Scholar
• Coers, J., Vance, R. E., Fontana, M. F. & Dietrich, W. F. Restriction of Legionella pneumophila growth in macrophages requires the concerted action of cytokine and Naip5/Ipaf signalling pathways. Cell. Microbiol. 9, 2344–2357 (2007).
  Article CAS PubMed Google Scholar
• Burger, D. & Travis, S. Conventional medical management of inflammatory bowel disease. Gastroenterology 140, 1827–1837 (2011).
  Article PubMed Google Scholar
• Musch, E., Andus, T., Malek, M., Chrissafidou, A. & Schulz, M. Successful treatment of steroid refractory active ulcerative colitis with natural interferon-β — an open long-term trial. Z. Gastroenterol. 45, 1235–1240 (2007).
  Article CAS PubMed Google Scholar
• Nikolaus, S. et al. Interferon β-1a in ulcerative colitis: a placebo controlled, randomised, dose escalating study. Gut 52, 1286–1290 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Madsen, S. M. et al. An open-labeled, randomized study comparing systemic interferon-α-2A and prednisolone enemas in the treatment of left-sided ulcerative colitis. Am. J. Gastroenterol. 96, 1807–1815 (2001).
  CAS PubMed Google Scholar
• Pena Rossi, C. et al. Interferon β-1a for the maintenance of remission in patients with Crohn's disease: results of a phase II dose-finding study. BMC Gastroenterol. 9, 22 (2009).
  Article PubMed CAS PubMed Central Google Scholar
• Pena-Rossi, C. et al. Clinical trial: a multicentre, randomized, double-blind, placebo-controlled, dose-finding, phase II study of subcutaneous interferon-β-1a in moderately active ulcerative colitis. Aliment. Pharmacol. Ther. 28, 758–767 (2008).
  Article CAS PubMed Google Scholar
• Gasche, C. et al. Prospective evaluation of interferon-α in treatment of chronic active Crohn's disease. Dig. Dis. Sci. 40, 800–804 (1995).
  Article CAS PubMed Google Scholar
• Musch, E. et al. Interferon-β-1a for the treatment of steroid-refractory ulcerative colitis: a randomized, double-blind, placebo-controlled trial. Clin. Gastroenterol. Hepatol. 3, 581–586 (2005).
  Article CAS PubMed Google Scholar
• Mitoro, A. et al. Exacerbation of ulcerative colitis during α-interferon therapy for chronic hepatitis C. Intern. Med. 32, 327–331 (1993).
  Article CAS PubMed Google Scholar
• Watanabe, T. et al. A case of exacerbation of ulcerative colitis induced by combination therapy with PEG-interferon α-2b and ribavirin. Gut 55, 1682–1683 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Schott, E. et al. Development of ulcerative colitis in a patient with multiple sclerosis following treatment with interferon β1a. World J. Gastroenterol. 13, 3638–3640 (2007).
  Article PubMed PubMed Central Google Scholar
• Freeman, H. J., Chopra, A., Clandinin, M. T. & Thomson, A. B. Recent advances in celiac disease. World J. Gastroenterol. 17, 2259–2272 (2011).
  Article PubMed PubMed Central Google Scholar
• MacDonald, T. T. & Spencer, J. Evidence that activated mucosal T cells play a role in the pathogenesis of enteropathy in human small intestine. J. Exp. Med. 167, 1341–1349 (1988).
  Article CAS PubMed Google Scholar
• Neurath, M. F., Finotto, S. & Glimcher, L. H. The role of Th1/Th2 polarization in mucosal immunity. Nature Med. 8, 567–573 (2002).
  Article CAS PubMed Google Scholar
• Monteleone, G., Pender, S. L., Wathen, N. C. & MacDonald, T. T. Interferon-α drives T cell-mediated immunopathology in the intestine. Eur. J. Immunol. 31, 2247–2255 (2001).
  Article CAS PubMed Google Scholar
• Di Sabatino, A. et al. Evidence for the role of interferon-alfa production by dendritic cells in the Th1 response in celiac disease. Gastroenterology 133, 1175–1187 (2007).
  Article CAS PubMed Google Scholar
• Molberg, O. et al. Tissue transglutaminase selectively modifies gliadin peptides that are recognized by gut-derived T cells in celiac disease. Nature Med. 4, 713–717 (1998).
  Article CAS PubMed Google Scholar
• Molberg, O. et al. Gliadin specific, HLA DQ2-restricted T cells are commonly found in small intestinal biopsies from coeliac disease patients, but not from controls. Scand. J. Immunol. 46, 103–109 (1997).
  Article CAS PubMed Google Scholar
• Kagnoff, M. F. Celiac disease: pathogenesis of a model immunogenetic disease. J. Clin. Invest. 117, 41–49 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Ting, J. P. & Trowsdale, J. Genetic control of MHC class II expression. Cell 109, S21–S33 (2002).
  Article CAS PubMed Google Scholar
• Cammarota, G., Cuoco, L., Cianci, R., Pandolfi, F. & Gasbarrini, G. Onset of coeliac disease during treatment with interferon for chronic hepatitis C. Lancet 356, 1494–1495 (2000).
  Article CAS PubMed Google Scholar
• Zheng, Y. et al. Interleukin-22, a TH17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 445, 648–651 (2007).
  CAS PubMed Google Scholar
• Nestle, F. O. et al. Plasmacytoid predendritic cells initiate psoriasis through interferon-α production. J. Exp. Med. 202, 135–143 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Dzionek, A. et al. BDCA-2, a novel plasmacytoid dendritic cell-specific type II C-type lectin, mediates antigen capture and is a potent inhibitor of interferon α/β induction. J. Exp. Med. 194, 1823–1834 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Hua, J., Kirou, K., Lee, C. & Crow, M. K. Functional assay of type I interferon in systemic lupus erythematosus plasma and association with anti-RNA binding protein autoantibodies. Arthritis Rheum. 54, 1906–1916 (2006).
  Article CAS PubMed Google Scholar
• Kirou, K. A. et al. Activation of the interferon-α pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. Arthritis Rheum. 52, 1491–1503 (2005).
  Article CAS PubMed Google Scholar
• Blanco, P., Palucka, A. K., Gill, M., Pascual, V. & Banchereau, J. Induction of dendritic cell differentiation by IFN-α in systemic lupus erythematosus. Science 294, 1540–1543 (2001).
  Article CAS PubMed Google Scholar
• Jego, G. et al. Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6. Immunity 19, 225–234 (2003).
  Article CAS PubMed Google Scholar
• Yao, Y. et al. Neutralization of interferon-α/β-inducible genes and downstream effect in a phase I trial of an anti-interferon-α monoclonal antibody in systemic lupus erythematosus. Arthritis Rheum. 60, 1785–1796 (2009).
  Article CAS PubMed Google Scholar
• Ann Marrie, R. & Rudick, R. A. Drug insight: interferon treatment in multiple sclerosis. Nature Clin. Pract. Neurol. 2, 34–44 (2006).
  Article CAS Google Scholar
• Bendtzen, K. Critical review: assessment of interferon-β immunogenicity in multiple sclerosis. J. Interferon Cytokine Res. 30, 759–766 (2010).
  Article CAS PubMed Google Scholar
• The IFNB Multiple Sclerosis Study Group. Interferon β-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43, 655–661 (1993).
• Teige, I. et al. IFN-β gene deletion leads to augmented and chronic demyelinating experimental autoimmune encephalomyelitis. J. Immunol. 170, 4776–4784 (2003).
  Article CAS PubMed Google Scholar
• Brod, S. A. & Burns, D. K. Suppression of relapsing experimental autoimmune encephalomyelitis in the SJL/J mouse by oral administration of type I interferons. Neurology 44, 1144–1148 (1994).
  Article CAS PubMed Google Scholar
• Prinz, M. et al. Distinct and nonredundant in vivo functions of IFNAR on myeloid cells limit autoimmunity in the central nervous system. Immunity 28, 675–686 (2008).
  Article CAS PubMed Google Scholar
• Guo, B., Chang, E. Y. & Cheng, G. The type I IFN induction pathway constrains Th17-mediated autoimmune inflammation in mice. J. Clin. Invest. 118, 1680–1690 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Teige, I., Liu, Y. & Issazadeh-Navikas, S. IFN-β inhibits T cell activation capacity of central nervous system APCs. J. Immunol. 177, 3542–3553 (2006).
  Article CAS PubMed Google Scholar
• Rudick, R. A. et al. Interferon β induces interleukin-10 expression: relevance to multiple sclerosis. Ann. Neurol. 40, 618–627 (1996).
  Article CAS PubMed Google Scholar
• Ferrantini, M., Capone, I. & Belardelli, F. Interferon-α and cancer: mechanisms of action and new perspectives of clinical use. Biochimie 89, 884–893 (2007).
  Article CAS PubMed Google Scholar
• Rizza, P., Moretti, F. & Belardelli, F. Recent advances on the immunomodulatory effects of IFN-α: implications for cancer immunotherapy and autoimmunity. Autoimmunity 43, 204–209 (2010).
  Article CAS PubMed Google Scholar
• Ferrantini, M. & Belardelli, F. Gene therapy of cancer with interferon: lessons from tumor models and perspectives for clinical applications. Semin. Cancer Biol. 10, 145–157 (2000).
  Article CAS PubMed Google Scholar
• Di Pucchio, T. et al. Immunization of stage IV melanoma patients with Melan-A/MART-1 and gp100 peptides plus IFN-α results in the activation of specific CD8+ T cells and monocyte/dendritic cell precursors. Cancer Res. 66, 4943–4951 (2006).
  Article CAS PubMed Google Scholar
• Lapenta, C. et al. IFN-α-conditioned dendritic cells are highly efficient in inducing cross-priming CD8+ T cells against exogenous viral antigens. Eur. J. Immunol. 36, 2046–2060 (2006).
  Article CAS PubMed Google Scholar
• Lapenta, C. et al. Potent immune response against HIV-1 and protection from virus challenge in hu-PBL-SCID mice immunized with inactivated virus-pulsed dendritic cells generated in the presence of IFN-α. J. Exp. Med. 198, 361–367 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Santodonato, L. et al. Monocyte-derived dendritic cells generated after a short-term culture with IFN-α and granulocyte-macrophage colony-stimulating factor stimulate a potent Epstein-Barr virus-specific CD8+ T cell response. J. Immunol. 170, 5195–5202 (2003).
  Article CAS PubMed Google Scholar